ASX - By Stock
|
IBX |
Re:
Ann: Entitlement Offer Offer Booklet
|
|
blutak
|
38 |
11K |
14 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
38
|
11K
|
14
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Quarterly Activity Report and Appendix 4C
|
|
blutak
|
9 |
3.8K |
2 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
9
|
3.8K
|
2
|
|
ASX - By Stock
|
RNT |
Re:
RentPay Discussion
|
|
blutak
|
19 |
5.7K |
2 |
11/11/22 |
11/11/22 |
ASX - By Stock
|
19
|
5.7K
|
2
|
|
ASX - By Stock
|
IBX |
Re:
JOURNEY to 50c plus
|
|
blutak
|
605 |
225K |
6 |
04/08/22 |
04/08/22 |
ASX - By Stock
|
605
|
225K
|
6
|
|
ASX - By Stock
|
IBX |
Re:
JOURNEY to 50c plus
|
|
blutak
|
605 |
225K |
29 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
605
|
225K
|
29
|
|
ASX - By Stock
|
RNT Technology |
Re:
Chart Thread
|
|
blutak
|
211 |
137K |
7 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
211
|
137K
|
7
|
|
ASX - By Stock
|
LGP |
Re:
Ann: Quarterly Activities Report & Appendix 4C
|
|
blutak
|
7 |
4.7K |
1 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
7
|
4.7K
|
1
|
|
ASX - By Stock
|
4DX |
Re:
Ann: Quarterly Activity Report and Appendix 4C for Q3 FY2022
|
|
blutak
|
4 |
3.8K |
2 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
4
|
3.8K
|
2
|
|
ASX - By Stock
|
BUD |
Re:
Ann: Appointment of Receivers and Managers
|
|
blutak
|
132 |
90K |
9 |
14/04/22 |
14/04/22 |
ASX - By Stock
|
132
|
90K
|
9
|
|
ASX - By Stock
|
BUD |
Re:
Ann: Appointment of Receivers and Managers
|
|
blutak
|
132 |
90K |
2 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
132
|
90K
|
2
|
|
ASX - By Stock
|
NUH |
Re:
Ann: Nuheara Submits 510(k) for U.S. FDA Clearance
|
|
blutak
|
31 |
11K |
5 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
31
|
11K
|
5
|
|
ASX - By Stock
|
IBX |
Re:
Ann: 2021 Annual Report to Shareholders
|
|
blutak
|
163 |
58K |
15 |
15/03/22 |
15/03/22 |
ASX - By Stock
|
163
|
58K
|
15
|
|
ASX - By Stock
|
IHL |
Re:
Ann: IHL-42X positive phase 2 clinical trial results
|
|
blutak
|
389 |
160K |
8 |
11/03/22 |
11/03/22 |
ASX - By Stock
|
389
|
160K
|
8
|
|
ASX - By Stock
|
IHL |
Re:
Ann: IHL-42X positive phase 2 clinical trial results
|
|
blutak
|
389 |
160K |
2 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
389
|
160K
|
2
|
|
ASX - By Stock
|
BUD |
Re:
Ann: Non Cash Impairment
|
|
blutak
|
141 |
51K |
14 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
141
|
51K
|
14
|
|
ASX - By Stock
|
NUH |
Re:
Ann: H1 FY22 - Nuheara Well Placed to Grow
|
|
blutak
|
64 |
18K |
0 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
64
|
18K
|
0
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Trading Halt
|
|
blutak
|
31 |
11K |
4 |
11/01/22 |
11/01/22 |
ASX - By Stock
|
31
|
11K
|
4
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Imagion Biosystems December 2021 Investor Newsletter
|
|
blutak
|
65 |
20K |
0 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
65
|
20K
|
0
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
blutak
|
96 |
29K |
6 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
96
|
29K
|
6
|
|
ASX - By Stock
|
NUH |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
blutak
|
104 |
18K |
11 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
104
|
18K
|
11
|
|
ASX - By Stock
|
RNT |
Re:
Ann: Q1 FY22 Quarterly Activity Report and App 4C
|
|
blutak
|
24 |
10K |
6 |
27/10/21 |
27/10/21 |
ASX - By Stock
|
24
|
10K
|
6
|
|
ASX - By Stock
|
NUH |
Re:
Ann: Q1 FY22 Business Update and Investor Briefing Details
|
|
blutak
|
94 |
16K |
9 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
94
|
16K
|
9
|
|
ASX - By Stock
|
NUH |
Re:
Ann: Q1 FY22 Business Update and Investor Briefing Details
|
|
blutak
|
94 |
16K |
13 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
94
|
16K
|
13
|
|
ASX - By Stock
|
IBX |
Re:
Interesting
|
|
blutak
|
5.5K |
1.9M |
2 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
5.5K
|
1.9M
|
2
|
|
ASX - By Stock
|
LGP |
Re:
Ann: LGP expands into Psychedelic Medicines
|
|
blutak
|
21 |
7.7K |
4 |
07/09/21 |
07/09/21 |
ASX - By Stock
|
21
|
7.7K
|
4
|
|
ASX - By Stock
|
OSP |
Re:
Ann: Consolidation/Split - OSP
|
|
blutak
|
139 |
37K |
3 |
20/08/21 |
20/08/21 |
ASX - By Stock
|
139
|
37K
|
3
|
|
ASX - By Stock
|
OSP |
Re:
Ann: Appendix 4D Half Year Report & Accounts
|
|
blutak
|
3 |
1.5K |
2 |
17/08/21 |
17/08/21 |
ASX - By Stock
|
3
|
1.5K
|
2
|
|
ASX - By Stock
|
RNT |
Re:
Ann: June 2021 Quarterly Activities Report & 4C
|
|
blutak
|
49 |
17K |
1 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
49
|
17K
|
1
|
|
ASX - By Stock
|
RNT |
Re:
Ann: June 2021 Quarterly Activities Report & 4C
|
|
blutak
|
49 |
17K |
3 |
03/08/21 |
03/08/21 |
ASX - By Stock
|
49
|
17K
|
3
|
|
ASX - By Stock
|
BUD |
Re:
Ann: BUD June Quarterly 4C Review
|
|
blutak
|
63 |
23K |
2 |
01/08/21 |
01/08/21 |
ASX - By Stock
|
63
|
23K
|
2
|
|
ASX - By Stock
|
BUD |
Re:
Ann: BUD June Quarterly 4C Review
|
|
blutak
|
63 |
23K |
5 |
31/07/21 |
31/07/21 |
ASX - By Stock
|
63
|
23K
|
5
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
blutak
|
122 |
28K |
14 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
122
|
28K
|
14
|
|
ASX - By Stock
|
OSP |
Re:
Ann: Appendix 4C
|
|
blutak
|
13 |
4.8K |
5 |
29/07/21 |
29/07/21 |
ASX - By Stock
|
13
|
4.8K
|
5
|
|
ASX - By Stock
|
OSP |
Re:
Ann: CEO Investor Presentation
|
|
blutak
|
4 |
2.4K |
0 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
4
|
2.4K
|
0
|
|
ASX - By Stock
|
IBX |
Re:
Ann: First-in-human study update - First patient enrolled
|
|
blutak
|
529 |
181K |
6 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
529
|
181K
|
6
|
|
ASX - By Stock
|
IBX |
Re:
Ann: First-in-human study update - First patient enrolled
|
|
blutak
|
529 |
181K |
4 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
529
|
181K
|
4
|
|
ASX - By Stock
|
IBX |
Re:
Interesting
|
|
blutak
|
5.5K |
1.9M |
21 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
5.5K
|
1.9M
|
21
|
|
ASX - By Stock
|
RNT |
Re:
lacklustre & uncertain market conditions
|
|
blutak
|
23 |
12K |
1 |
13/05/21 |
13/05/21 |
ASX - By Stock
|
23
|
12K
|
1
|
|
ASX - By Stock
|
IBX |
Re:
Interesting
|
|
blutak
|
5.5K |
1.9M |
6 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
5.5K
|
1.9M
|
6
|
|
ASX - By Stock
|
IBX |
Re:
Interesting
|
|
blutak
|
5.5K |
1.9M |
13 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
5.5K
|
1.9M
|
13
|
|
ASX - By Stock
|
RNT |
Re:
Ann: RentPay Platform Launched to Public
|
|
blutak
|
146 |
61K |
1 |
06/05/21 |
06/05/21 |
ASX - By Stock
|
146
|
61K
|
1
|
|
ASX - By Stock
|
IBX |
Re:
Ann: Imagion and Patrys collaborate on new cancer imaging agents
|
|
blutak
|
60 |
25K |
3 |
05/05/21 |
05/05/21 |
ASX - By Stock
|
60
|
25K
|
3
|
|
ASX - By Stock
|
NUH |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
blutak
|
23 |
7.1K |
20 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
23
|
7.1K
|
20
|
|
ASX - By Stock
|
BUD |
Re:
Ann: Update on March Results - Financial Guidance
|
|
blutak
|
235 |
72K |
2 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
235
|
72K
|
2
|
|
ASX - By Stock
|
BUD |
Re:
Ann: Update on March Results - Financial Guidance
|
|
blutak
|
235 |
72K |
4 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
235
|
72K
|
4
|
|
ASX - By Stock
|
OSP |
Re:
Ann: CEO Business Update Investor Presentation
|
|
blutak
|
31 |
7.8K |
0 |
15/04/21 |
15/04/21 |
ASX - By Stock
|
31
|
7.8K
|
0
|
|
ASX - By Stock
|
NUH |
Re:
$1 party
|
|
blutak
|
109 |
31K |
18 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
109
|
31K
|
18
|
|
ASX - By Stock
|
NVX |
Re:
NOVONIX PRICE ACTION 2021
|
|
blutak
|
417 |
224K |
18 |
25/03/21 |
25/03/21 |
ASX - By Stock
|
417
|
224K
|
18
|
|
ASX - By Stock
|
OSP |
Re:
Ann: Expansion of US Sales Coverage
|
|
blutak
|
101 |
21K |
0 |
18/03/21 |
18/03/21 |
ASX - By Stock
|
101
|
21K
|
0
|
|
ASX - By Stock
|
OSP |
Re:
Ann: Expansion of US Sales Coverage
|
|
blutak
|
101 |
21K |
2 |
18/03/21 |
18/03/21 |
ASX - By Stock
|
101
|
21K
|
2
|
|